AlphAIAlphAI — Financial news for AI agents
investing.comOCT 232 min read$IDYA

IDEAYA reports IDE849 trial data in lung cancer, neuroendocrine tumors

IDEAYA Biosciences (NASDAQ:IDYA) shared Phase 1 trial results for IDE849, showing promising survival and response rates in lung cancer and neuroendocrine tumors. The study, presented by partner Hengrui, reported median overall survival of 17.4 months in second-line small cell lung cancer patients. IDEAYA plans Phase 3 trials following FDA meetings.

Original reporting
investing.com
Published Oct 23, 2026, 10:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 10:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$IDYA
Bullish
high confidence
Mentioned
$IDYA
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IDYABullishMed
01

Why it matters

The disclosed data provide a concrete catalyst that could move IDYA's share price in the short term.

02

Market read

First‑time release of promising early‑stage trial results for a novel oncology ADC, a material event for the stock.

03

What to watch

Potential regulatory hurdles and competition from other ADC platforms could limit upside.

Relevance 8/10Novelty 8/10Timing: today

Background

IDEAYA partnered with Jiangsu Hengrui and plans Phase 3 trials after presenting data at ESMO 2026.

Company-level read

Ticker impact

$IDYABullishHigh confidence
Context

IDEAYA Biosciences released new Phase 1 trial data for IDE849 showing high response rates and median overall survival in small cell lung cancer.

Expected impact

likely upside as market prices in the strong efficacy data

Evidence & confidence

The data are first‑time disclosed, show robust efficacy (ORR 68‑72%) and manageable safety, which are material for a biotech on the cusp of Phase 3.

Market effects

Sector

strengthens the small‑cell lung cancer therapeutic pipeline and may lift peer biotech stocks in oncology.

Regional

U.S. biotech sector may see modest gains.

Global

Adds optimism to global oncology drug development outlook.

Counterpoint

What could challenge this read

Investors may remain cautious until Phase 3 data confirm durability and safety.

Key entities

  • company
    IDEAYA Biosciences Inc.

    US‑listed biotech developing antibody‑drug conjugates.

  • partner
    Jiangsu Hengrui Pharmaceuticals

    Chinese pharma partner presenting the data.

Read at source← All news

StoryIDEAYA reports positive Phase 1 IDE849 data and plans two Phase 3 trials

Related articles

OCT 23
$IDYAHighAI 9/10

IDEAYA Reports Promising IDE849 Results In Small Cell Lung Cancer

IDEAYA Biosciences reported Phase 1 results for IDE849, showing antitumor activity in relapsed small cell lung cancer. Median overall survival was 17.4 months in second-line SCLC and 14.7 months across second-line and later-line patients. The confirmed response rate was 60.8% in second-line SCLC. IDEAYA plans Phase 3 trials. The stock closed at $36.12, up 1.83%, and is down 0.03% in premarket trading.

rttnews.com1 min
OCT 23
$IDYAHighAI 8/10

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas

IDEAYA Biosciences (IDYA) reported updated Phase 1 results for IDE849, its DLL3-targeting ADC, at ESMO 2026. The study showed promising anti-tumor activity and preliminary overall survival in relapsed SCLC and NECs, with median OS of 17.4 months in 2L SCLC and 14.7 months in 2L + ≥3L SCLC. IDEAYA plans to initiate Phase 3 trials for ES-SCLC and NEC, targeting initiation following successful FDA meetings.

prnewswire.com2 min
OCT 19
$IDYAMedAI 8/10

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

IDEAYA Biosciences and Servier presented clinical trial data at ESMO 2026, showing positive results for darovasertib in treating uveal melanoma. OptimUM-01 data showed 7.4-month PFS and 27.1-month mOS in treatment-naïve patients. OptimUM-02 data confirmed improvements in ORR and PFS across subgroups. OptimUM-09 data demonstrated 57% eye preservation rate and 66% radiation dose reduction in primary UM patients.

prnewswire.com2 min
SEP 25
$IDYAMedAI 8/10

Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?

IDEAYA Biosciences (IDYA) reported a widened quarterly net loss but maintains strong liquidity with $1.24B in cash. It dosed the first patient in a Phase 3 trial for darovasertib in uveal melanoma, sharing costs with partner Servier. The company is advancing its oncology pipeline while managing R&D costs, with regulatory approvals and commercial execution being key to its success.

insidermonkey.com3 min